您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Regadenoson
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Regadenoson
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Regadenoson图片
CAS NO:313348-27-5
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
50mg电议

产品介绍
Regadenoson (CVT-3146) 是一种选择性 A2A 腺苷受体激动剂和血管扩张剂,可增加冠状动脉血流,可用于心肌灌注成像研究。
Cas No.313348-27-5
别名瑞加德松; CVT-3146
化学名(Z)-1-(6-amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carbimidic acid
Canonical SMILESC/N=C(O)/C(C=N1)=CN1C2=NC(N)=C(N=CN3[C@@]4([H])[C@@](O)([H])[C@@](O)([H])[C@@](O4)([H])CO)C3=N2
分子式C15H18N8O5
分子量390.35
溶解度≥ 18.05mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Description:

Ki: 1095 nM for A2A receptor

The adenosine A2A receptor is a G-protein-coupled receptor that has been extensively studied during the past few decades because it offers numerous possibilities for therapeutic applications. Regadenoson (CVT-3146) is a highly selective, potent, low affinity A2A adenosine agonist.

In vitro: Regadenoson was selective for the A2A adenosine receptor versus the A1, A2B, and A3 receptors in binding and functional studies. Regadenoson was also found to be a full and potent agonist to cause coronary vasodilation, a response that has a very large A2A receptor reserve [1].

In vivo: In a study of 10 conscious dogs, authors compared intravenously injected regadenoson to that of adenosine. Regadenoson caused a dose-dependent increase of coronary blood flow (CBF), whereas adenosine was less potent but produced equivalent hyperemia. Thus, authors concluded that regadenoson is a potent coronary vasodilator with a short duration of action, minimal and transient systemic hemodynamic effects, and ease of administration [1].

Clinical trial: Previous study investigated the magnitude and duration of the effect of regadenoson on CBF velocity in humans. Results demonstrated that regadenoson produced a dose-dependent increase in duration of CBF velocity augmentation. At all dose levels, regadenoson caused a rapid increase in CBF velocity that was near peak within 30 seconds of the bolus delivery. Regadenoson was generally well tolerated, and side effects at all doses were infrequent, mild, and self-limited [1].

Reference:
[1] Cerqueira MD. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol. 2004 Jul 22;94(2A):33D-40D; discussion 40D-42D.